Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
57 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-9 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. is a biotechnology company that focuses on the development and commercialization of targeted therapies for the treatment of cancer and other diseases. The company's approach involves utilizing novel drug compounds and technologies to selectively deliver treatment to specific sites in the body, minimizing side effects and enhancing efficacy.
Novelos Therapeutics has a pipeline of drug candidates in various stages of development, including NOV-002, NOV-205, and NOV-301. NOV-002 is an injectable drug designed to enhance the effectiveness of chemotherapy and radiation therapy, while reducing their toxicity. NOV-205 is a compound that can selectively deliver therapeutic molecules to cancer cells. NOV-301 is being developed for the treatment of acute respiratory distress syndrome (ARDS), a severe lung condition.
The company's drug development strategy is based on extensive preclinical and clinical research, and they collaborate with academic institutions and industry partners to advance their programs. Novelos Therapeutics aims to provide safer and more effective treatment options for patients suffering from cancer and other serious diseases.
. and may not encompass all aspects of the company's operations and activities.
|